|
1.
|
|
9 p, 599.8 KB |
Reduced 8-Gray Compared to Standard 12-Gray Total Body Irradiation for Allogeneic Transplantation in First Remission Acute Lymphoblastic Leukemia : A Study of the Acute Leukemia Working Party of the EBMT
/
Spyridonidis, Alexandros (University of Patras) ;
Labopin, Myriam (Sorbonne University) ;
Savani, Bipin (Vanderbilt University Medical Center) ;
Giebel, Sebastian (Maria Sklodowska-Curie National Research Institute of Oncology) ;
Bug, Gesine (Department of Medicine II. Goethe-University) ;
Schönland, Stefan (Medical Department V. University Hospital Heidelberg) ;
Kröger, Nicolaus (Department of Stem Cell Transplantation. University Medical Center) ;
Stelljes, Matthias (Department of Hematology/Oncology. University of Muenster) ;
Schroeder, Thomas (Department of Bone Marrow Transplantation. University Hospital) ;
Mcdonald, Andrew (Netcare Pretoria East Hospital) ;
Blau, Igor-Wolfgang (Charité - Universitätsmedizin Berlin) ;
Bornhäuser, Martin (University Hospital. TU Dresden) ;
Rovira, Montse (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Bethge, Wolfgang (Department of Hematology & Oncology. University Hospital Tuebingen.) ;
Neubauer, Andreas (Philipps Universitaet Marburg) ;
Ganser, Arnold (Hannover Medical School) ;
Bourhis, Jean Henri (Gustave Roussy Cancer Campus BMT. Department of Hematology) ;
Edinger, Matthias (University Regensburg. Department of Hematology and Oncology) ;
Lioure, Bruno (Hematology. Stem Cell Transplant Unit. ICANS) ;
Wulf, Gerald (University Medicine Goettingen) ;
Schäfer-Eckart, Kerstin (Klinikum Nuernberg. 5. Medizinische Klinik. BMT-Unit) ;
Arat, Mutlu (Demiroglu Bilim Univ. Istanbul Florence Nightingale Hospital) ;
Peric, Zinaida (University Hospital Centre) ;
Schmid, Christoph (Universitatsklinikum Augsburg. Section Stem Cell Transplantation. Augsburg University and Medical Faculty) ;
Bazarbachi, Ali (Bone Marrow Transplantation Program. Department of Internal Medicine. American University of Beirut-Medical Center) ;
Ciceri, Fabio (Ospedale San Raffaele) ;
Nagler, Arnon (Hematology Division. Chaim Sheba Medical Center) ;
Mohty, Mohamad (Sorbonne Université)
In this registry-based study, we compared outcomes of allogeneic hematopoietic cell transplantation (allo-HCT) in adult patients with acute lymphoblastic leukemia (ALL) transplanted in first complete remission (CR-1), following conditioning with total body irradiation (TBI) at a standard 12-Gray or at a lower 8-Gray total dose. [...]
2023 -  10.1097/HS9.0000000000000812
HemaSphere, Vol. 7 Núm. 1 (september 2023) , p. e812
|
|
|
2.
|
|
12 p, 804.5 KB |
RIC versus MAC UCBT in adults with AML : A report from Eurocord, the ALWP and the CTIWP of the EBMT
/
Baron, Frédéric (University of Liege) ;
Ruggeri, Annalisa (Hôpital Saint-Antoine (Paris, França)) ;
Beohou, Eric (Hôpital Saint-Antoine (Paris, França)) ;
Labopin, Myriam (Hôpital Saint-Antoine (Paris, França)) ;
Sanz, Guillermo (Hospital Universitari i Politècnic La Fe (València)) ;
Milpied, Noel (University of Bordeaux) ;
Michallet, Mauricette (Centre Hospitalier de Lyon Sud) ;
Bacigalupo, Andrea (Ospedale San Martino) ;
Blaise, Didier (Aix-Marseille Université) ;
Malouf Sierra, Jorge 1971- (Institut d'Investigació Biomèdica Sant Pau) ;
Socié, Gérard (Hospital Saint-Louis) ;
Cornelissen, Jan J. (Erasmus Medical Center-Daniel den Hoed Cancer Center) ;
Schmid, Christoph (University of Munich) ;
Giebel, Sebastian (Gliwice Branch) ;
Gorin, Norbert-Claude (Hospital Saint Antoine) ;
Esteve, Jordi (Hematology. Hospital Clinic) ;
Ciceri, Fabio (Ospedale San Raffaele) ;
Savani, Bipin N. (Vanderbilt University Medical Center) ;
Mohty, Mohamad (UMRs 938) ;
Gluckman, Eliane (Centre Scientifique de Monaco) ;
Nagler, Arnon (The Chaim Sheba Medical Center) ;
Universitat Autònoma de Barcelona
Nonrelapse mortality (NRM) is the first cause of treatment failure after unrelated cord blood transplantation (UCBT) following myeloablative conditioning (MAC). In the last decade, reduced-intensity conditioning (RIC) regimens have been developed with the aim of reducing NRM and allowing older patients and those with medical comorbidities to benefit from UCBT. [...]
2016 - 10.18632/oncotarget.9599
Oncotarget, Vol. 7 Núm. 28 (2016) , p. 43027-43038
|
|
|
3.
|
|
10 p, 786.4 KB |
Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation : An EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine
/
Giannotti, Federica (Saint-Antoine Hospital) ;
Labopin, Myriam (Hôpital Saint-Antoine (Paris, França)) ;
Shouval, Roni (Chaim Sheba Medical Center (Israel)) ;
Sanz, Jaime (Instituto de Salud Carlos III) ;
Arcese, William (Rome Transplant Network tor Vergatä) ;
Angelucci, Emanuele (Ospedale Policlinico San Martino) ;
Malouf Sierra, Jorge 1971- (Institut d'Investigació Biomèdica Sant Pau) ;
Ribera, Jose-Maria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Santarone, Stella (Ospedale Civile) ;
Benedetto, Bruno (S.S.C.V.D Trapianto di Cellule Staminali A.O.U Citta della Salute e della Scienza di Torino) ;
Rambaldi, Alessandro (Azienda Ospedaliera Papa Giovanni XXIII) ;
Saccardi, Riccardo (Azienda Ospedaliera Universitaria Careggi) ;
Blaise, Didier (Institut Paoli Calmettes) ;
Carella, Michele Angelo (IRCCS) ;
Rocha, Vanderson (Universidade de São Paulo) ;
Baron, Frederic (University of Liege) ;
Mohty, Mohamad (Hospital Saint- Antoine) ;
Ruggeri, Annalisa (Ospedale Pediatrico Bambino Gesù (Roma, Itàlia)) ;
Nagler, Arnon (Tel-Aviv University) ;
Universitat Autònoma de Barcelona
Thiotepa-busulfan-fludarabine (TBF) is a widely used conditioning regimen in single umbilical cord blood transplantation (SUCBT). More recently, it was introduced in the setting of non-T cell depleted haploidentical stem cell transplantation (NTD-Haplo). [...]
2018 - 10.1186/s13045-018-0655-8
Journal of hematology & oncology, Vol. 11 Núm. 1 (30 2018) , p. 110
|
|
|
4.
|
|
6 p, 657.1 KB |
Outcomes of Advanced Hodgkin Lymphoma after Umbilical Cord Blood Transplantation : A Eurocord and EBMT Lymphoma and Cellular Therapy & Immunobiology Working Party Study
/
Paviglianiti, Annalisa (Centre Scientifique de Monaco) ;
Tozatto Maio, Karina (Centre Scientifique de Monaco) ;
Rocha, Vanderson (Hospital Sao Paulo) ;
Gehlkopf, Eve (CHU Lapeyronie) ;
Milpied, Noel (CHU Bordeaux) ;
Esquirol, Albert (Institut d'Investigació Biomèdica Sant Pau) ;
Chevallier, Patrice (Hospital Hotel Dieu (Nantes, França)) ;
Blaise, Didier (Institute Paoli Calmettes) ;
Gac, Anne-Claire (Institut d'Hématologie de Basse-Normandie) ;
Leblond, Véronique (Hopital la Pitié-Salpêtrière) ;
Cahn, Jean-Yves (CHU Grenoble Alpes) ;
Abecasis, Manuel (Institute Portugues Oncologia) ;
Zuckerman, Tsila (Rambam Medical Center) ;
Schouten, Harry (University Hospital Maastricht) ;
Gurman, Gunhan (Ankara University) ;
Rubio, Marie Thérèse (Hôpitaux des Brabois) ;
Beguin, Yves (CHU of Liège and University of Liege) ;
Corral, Lucia Lopez (Centro de Investigacion del Cancer-IBMCC) ;
Nagler, Amon (Chaim Sheba Medical Center (Israel)) ;
Snowden, John A. (Sheffield Teaching Hospitals NHS Trust) ;
Koc, Yener (Stem Cell Transplant Unit Medical Park Hospitals) ;
Mordini, Nicola (Az. Ospedaliera S. Croce e Carle) ;
Bonifazi, Francesca ("Seragnoli" University Hospital S. Orsola-Malpighi) ;
Volt, Fernanda (Centre Scientifique de Monaco) ;
Kenzey, Chantal (Centre Scientifique de Monaco) ;
Robinson, Stephen Paul (EBMT Lymphoma Working Party) ;
Montoto, Silvia (EBMT Lymphoma Working Party) ;
Gluckman, Eliane (Centre Scientifique de Monaco) ;
Ruggeri, Annalisa (Bambin Gesù) ;
Universitat Autònoma de Barcelona
Allogeneic stem cell transplantation is an alternative for patients with relapsed or refractory Hodgkin lymphoma (HL), but only limited data on unrelated umbilical cord blood transplantation (UCBT) are available. [...]
2018 - 10.1016/j.bbmt.2018.07.019
Biology of blood and marrow transplantation, Vol. 24 Núm. 11 (november 2018) , p. 2265-2270
|
|
|
5.
|
|
13 p, 1.7 MB |
A prospective non-interventional study on the impact of transfusion burden and related iron toxicity on outcome in myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplantation
/
Cremers, Eline M.P. (VU University Medical Centre) ;
de Witte, Theo (Radboud University Medical Centre) ;
de Wreede, Liesbeth C. (Leiden University Medical Center) ;
Eikema, Diderik-Jan (EBMT Statistical Unit Data Office Leiden) ;
Koster, Linda (EBMT Data Office Leiden) ;
van Biezen, Anja (EBMT Data Office Leiden) ;
Finke, Jürgen (University of Freiburg) ;
Socié, Gerard (Hospital St. Louis) ;
Beelen, Dietrich (University Hospital) ;
Maertens, Johan (University Hospitals Gasthuisberg (Leuven, Bélgica)) ;
Nagler, Arnon (Chaim Sheba Medical Center (Israel)) ;
Kobbe, Guido (Heinrich Heine Universitaet) ;
Ziagkos, Dimitris (EBMT Statistical Unit Data Office Leiden) ;
Itälä-Remes, Maija (HUCH Comprehensive Cancer Center) ;
Gedde-Dahl, Tobias (Oslo University Hospital (Oslo, Noruega)) ;
Sierra, Jorge (Institut d'Investigació Biomèdica Sant Pau) ;
Niederwieser, Dietger (University Hospital Leipzig) ;
Ljungman, Per (Karolinska University Hospital and Karolinska Institutet (Suecia)) ;
Beguin, Yves (University of Liège) ;
Ozkurt, Zubeyde Nur (Gazi University) ;
Anagnostopoulos, Achilles (George Papanicolaou General Hospital (Tessalònia, Grècia)) ;
Jindra, Pavel (Charles University Hospital) ;
Robin, Marie (Hospital St. Louis) ;
Kröger, Nicolaus (University Hospital Eppendorf) ;
Universitat Autònoma de Barcelona
Most myelodysplastic syndromes (MDS)-patients receive multiple red blood cell transfusions (RBCT). Transfusions may cause iron-related toxicity and mortality, influencing outcome after allogeneic HSCT. [...]
2019 - 10.1080/10428194.2019.1594215
Leukemia and Lymphoma, Vol. 60 Núm. 10 (2019) , p. 2404-2414
|
|
|
6.
|
|
8 p, 440.5 KB |
Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation : A Report on Behalf of the American Society for Transplantation and Cellular Therapy
/
Kharfan-Dabaja, Mohamed A. (Mayo Clinic. Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapies Program) ;
Kumar, Ambuj (Program for Comparative Effectiveness Research. Morsani College of Medicine. University of South Florida) ;
Ayala, Ernesto (Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapies Program. Mayo Clinic) ;
Aljurf, Mahmoud (Department of Adult Hematology and Stem Cell Transplantation. King Faisal Specialist Hospital and Research Centre) ;
Nishihori, Taiga (Department of Blood and Marrow Transplantation and Cellular Immunotherapy. Moffitt Cancer Center) ;
Marsh, Rebecca (Cincinnati Children's Hospital Medical Center) ;
Burroughs, Laura M. (Fred Hutchinson Cancer Research Center) ;
Majhail, Navneet (Blood and Marrow Transplant Program. Taussig Cancer Institute. Cleveland Clinic) ;
Al-Homsi, Ahmad Samer (NYU Langone Health) ;
Al-Kadhimi, Zaid S. (Division of Oncology and Hematology. Department of Internal Medicine. University of Nebraska Medical Center) ;
Bar, Merav (Fred Hutchinson Cancer Research Center) ;
Bertaina, Alice (Division of Stem Cell Transplant and Regenerative Medicine. Department of Pediatrics. Stanford University) ;
Boelens, Jaap Jan (Stem Cell Transplantation and Cellular Therapies Program. Department Pediatrics. Memorial Sloan Kettering Cancer Center) ;
Champlin, Richard (Department of Stem Cell Transplantation and Cellular Therapy. The University of Texas MD Anderson Cancer Center) ;
Chaudhury, Sonali (Ann and Robert H. Lurie Children's Hospital of Chicago) ;
DeFilipp, Zachariah (Department of Hematology-Oncology and Hematopoietic Cell Transplant and Cellular Therapy Program. Massachusetts General Hospital) ;
Dholaria, Bhagirathbhai (Vanderbilt University Medical Center) ;
El-Jawahri, Areej (Department of Hematology-Oncology and Hematopoietic Cell Transplant and Cellular Therapy Program. Massachusetts General Hospital) ;
Fanning, Suzanne (Blood and Marrow Transplant Program. University of South Carolina School of Medicine) ;
Fraint, Ellen (Stem Cell Transplantation and Cellular Therapies Program. Department Pediatrics. Memorial Sloan Kettering Cancer Center) ;
Gergis, Usama (Bone Marrow Transplant and Immune Cellular Therapy. Thomas Jefferson University Hospital) ;
Giralt, Sergio (Department of Medicine. Division of Hematologic Malignancies. Memorial Sloan Kettering Cancer Center Weill Cornell Medical College) ;
Hamilton, Betty K. (Blood and Marrow Transplant Program. Taussig Cancer Institute. Cleveland Clinic) ;
Hashmi, Shahrukh K (Department of Medicine. Sheikh Shakhbout Medical City) ;
Horn, Biljana (Department of Pediatrics. Division of Hematology/Oncology. University of Florida. UF Health Shands Children's Hospital) ;
Inamoto, Yoshihiro (National Cancer Center Hospital) ;
Jacobsohn, David A. (Children's National Medical Center) ;
Jain, Tania (Johns Hopkins University School of Medicine) ;
Johnston, Laura (Stanford University School of Medicine) ;
Kanate, Abraham S. (West Virginia University) ;
Kansagra, Ankit (UT Southwestern Medical Center) ;
Kassim, Adetola (Vanderbilt University Medical Center) ;
Kean, Leslie S. (Boston Children's Hospital. Dana-Farber Cancer Institute) ;
Kitko, Carrie L. (Vanderbilt University Medical Center) ;
Knight-Perry, Jessica (University of Colorado School of Medicine) ;
Kurtzberg, Joanne (Duke University School of Medicine) ;
Liu, Hien (Moffitt Cancer Center) ;
MacMillan, Margaret L (University of Minnesota Medical School) ;
Mahmoudjafari, Zahra (University of Kansas Cancer Center) ;
Mielcarek, Marco (Fred Hutchinson Cancer Research Center) ;
Mohty, Mohamad (Sorbonne Université. INSERM. Centre de Recherche Saint-Antoine and Hôpital Saint-Antoine. Service d'Hématologie Clinique et Thérapie Cellulaire) ;
Nagler, Arnon (Chaim Sheba Medical Center (Israel)) ;
Nemecek, Eneida (Oregon Health & Science University) ;
Olson, Timothy S. (Children's Hospital of Philadelphia (Pennsilvània)) ;
Oran, Betul (The University of Texas MD Anderson Cancer Center) ;
Perales, Miguel Angel (Memorial Sloan Kettering Cancer Center Weill Cornell Medical College) ;
Prockop, Susan E. (Stem Cell Transplantation and Cellular Therapies Program. Department Pediatrics. Memorial Sloan Kettering Cancer Center) ;
Pulsipher, Michael A. (Children's Hospital Los Angeles Cancer and Blood Disease Institute. USC Keck School of Medicine) ;
Pusic, Iskra (Washington University School of Medicine) ;
Riches, Marcie L. (University of North Carolina at Chapel Hill) ;
Rodriguez, Cesar (Wake Forest University School of Medicine) ;
Romee, Rizwan (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Rondon, Gabriela (The University of Texas MD Anderson Cancer Center) ;
Saad, Ayman (The Ohio State University. Division of Hematology) ;
Shah, Nina (University of California San Francisco. Department of Medicine) ;
Shaw, Peter J. (The Children's Hospital at Westmead) ;
Shenoy, Shalini (Washington University School of Medicine) ;
Sierra, Jorge (Institut d'Investigació Biomèdica Sant Pau) ;
Talano, Julie (Children's Hospital of Wisconsin) ;
Verneris, Michael R. (University of Colorado School of Medicine) ;
Veys, Paul (University College London. Great Ormond Street Hospital.) ;
Wagner, John E. (University of Minnesota Medical School) ;
Savani, Bipin N. (Vanderbilt University Medical Center) ;
Hamadani, Mehdi (Medical College of Wisconsin) ;
Carpenter, Paul A. (Fred Hutchinson Cancer Research Center) ;
Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras ;
Universitat Autònoma de Barcelona.
Departament de Medicina
Allogeneic hematopoietic cell transplantation (allo-HCT) is potentially curative for certain hematologic malignancies and nonmalignant diseases. The field of allo-HCT has witnessed significant advances, including broadening indications for transplantation, availability of alternative donor sources, less toxic preparative regimens, new cell manipulation techniques, and novel GVHD prevention methods, all of which have expanded the applicability of the procedure. [...]
2021 - 10.1016/j.jtct.2021.04.007
Transplantation and Cellular Therapy, Vol. 27 Núm. 8 (august 2021) , p. 642-649
|
|
|
7.
|
|
8 p, 732.8 KB |
Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation
/
Gagelmann, N. (University Medical Center Hamburg-Eppendorf) ;
Eikema, D. J. (EBMT Statistics) ;
Stelljes, M. (University of Münster) ;
Beelen, D. (University Hospital Essen (Alemanya)) ;
de Wreede, Liesbeth C (EBMT Statistics) ;
Mufti, G. (GKT School of Medicine) ;
Knelange, N. S. (EBMT Data Office) ;
Niederwieser, D. (University Hospital Leipzig) ;
Friis, L. S. (University of Copenhagen) ;
Ehninger, Gerhard (Universitätsklinikum Dresden) ;
Nagler, Arnon (Chaim Sheba Medical Center (Israel)) ;
Yakoub-Agha, Ibrahim (Université Lille2) ;
Meijer, E. (Amsterdam UMC. University Medical Center) ;
Ljungman, Per (Karolinska University Hospital and Karolinska Institutet (Suècia)) ;
Maertens, Johan (University Hospitals Gasthuisberg (Leuven, Bélgica)) ;
Kanz, L. (Universität Tübingen) ;
Lopez-Corral, L. (Hospital Clínico Universitario (Salamanca)) ;
Brecht, A. (Deutsche Klinik für Diagnostik) ;
Craddock, Charles (Centre for Clinical Haematology) ;
Finke, J. (University of Freiburg) ;
Cornelissen, J. J. (Erasmus MC Cancer Institute. Erasmus University Medical Center) ;
Bernasconi, P. (Fondazione IRCCS Policlinico San Matteo) ;
Chevallier, Patrice (CHU Nantes) ;
Sierra, Jorge (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Robin, M. (Hopital St. Louis) ;
Kroeger, Nicolaus (University Medical Center Hamburg-Eppendorf) ;
Universitat Autònoma de Barcelona
The aim of this study was to develop and validate a clinical and transplant-specific prognostic score using data from a large cohort of patients with myelodysplastic syndromes reported to the European Society for Blood and Marrow Transplantation registry. [...]
2019 - 10.3324/haematol.2018.200808
Haematologica, Vol. 104 Núm. 5 (30 2019) , p. 929-936
|
|
|
8.
|
|
13 p, 1.0 MB |
Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia : A comparative study of the ALWP EBMT
/
Sanz, Jaime (Centro de Investigación Biomédica en Red de Cáncer) ;
Galimard, J. E. (EBMT Paris Office. Hospital Saint Antoine) ;
Labopin, Myriam (Department of Hematology. Hopital Saint Antoine. Sorbonne University) ;
Afanasyev, B. (First State Pavlov Medical University of St. Petersburg. Raisa Gorbacheva Mem. Research Institute for Paediatric Oncology. Hematology. and Transplantation) ;
Angelucci, Emanuele (Department of Haematology. IRCCS Ospedale Policlinico San Martino) ;
Ciceri, Fabio (Haematology and BMT) ;
Blaise, Didier (Programme de Transplantation and Therapie Cellulaire. Centre de Recherche en Cancérologie de Marseille. Institut Paoli Calmettes) ;
Cornelissen, J. J. (Department of Hematology. Erasmus MC Cancer Institute. University Medical Center Rotterdam) ;
Meijer, E. (Department of Hematology (Br 250). VU University Medical Center) ;
Diez-Martin, J. L. (Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM)) ;
Koc, Y. (Stem Cell Transplant Unit. Medical Park Hospitals) ;
Rovira Tarrats, Montserrat (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Castagna, L. (Transplantation Unit. Department of Oncology and Haematology. Istituto Clinico Humanitas) ;
Savani, B. N. (Vanderbilt University Medical Center) ;
Ruggeri, Annalisa (Ospedale Pediatrico Bambino Gesù (Roma, Itàlia)) ;
Nagler, Arnon (ALWP of the EBMT Office. Saint Antoine Hospital) ;
Mohty, Mohamad (Department of Hematology. Hopital Saint Antoine. Sorbonne University) ;
Universitat Autònoma de Barcelona
Background: The use of post-transplant cyclophosphamide (PTCy) is highly effective in preventing graft-versus-host disease (GVHD) in the haploidentical (Haplo) transplant setting and is being increasingly used in matched sibling (MSD) and matched unrelated (MUD) transplants. [...]
2020 - 10.1186/s13045-020-00882-6
Journal of hematology & oncology, Vol. 13 Núm. 1 (june 2020) , p. 46
|
|
|
9.
|
|
11 p, 572.5 KB |
Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients : a position statement from an international expert group
/
Mohty, Mohamad (Hematology Department. AP-HP. Hôpital Saint-Antoine. Sorbonne Université) ;
Malard, F. (Hematology Department. AP-HP. Hôpital Saint-Antoine. Sorbonne Université) ;
Abecasis, Manuel (Instituto Portugues de Oncologia) ;
Aerts, E. (University Hospital Zurich (Suïssa)) ;
Alaskar, A. S. (Department of Oncology. King Abdulaziz Medical City. King Abdullah International Medical Research Center. King Saud Bin Abdulaziz University for Health Sciences. Ministry of National Guard Health Affairs) ;
Aljurf, Mahmoud (King Faisal Specialist Hospital and Research Centre) ;
Arat, Mutlu (HSCT Unit. Sisli Florence Nightingale Hospital) ;
Bader, Peter (Division for Stem Cell Transplantation and Immunology. Department for Children and Adolescents. University Hospital. Goethe University) ;
Baron, Frederic (CHU and University of Liege) ;
Basak, G. (Medical University of Warsaw) ;
Bazarbachi, A. (American University of Beirut. Department of Internal Medicine) ;
Blaise, Didier (Transplant and Cellular Immunotherapy Program. Department of Hematology. Aix-Marseille Univ. Inserm. CNRS. Institut Paoli-Calmettes. CRCM) ;
Ciceri, Fabio (Hematology and Bone Marrow Transplantation Unit. IRCCS Ospedale San Raffaele. University Vita-Salute) ;
Corbacioglu, Selim (Department of Pediatric Hematology. Oncology and Stem Cell Transplantation. University of Regensburg) ;
Dalle, J. H. (Department of Hematology and Immunology. Hospital Robert Debre. Paris 7-Paris Diderot University) ;
Dignan, F. (Department of Clinical Haematology. Central Manchester Foundation Trust) ;
Fukuda, T. (HSCT Division. National Cancer Center Hospital) ;
Huynh, A. (Institut Universitaire du Cancer Toulouse-Oncopole) ;
Kuball, J. (Department of Haematology. University Medical Centre) ;
Lachance, S. (Department of Hematology and Stem Cell Transplant Program. Hôpital Maisonneuve-Rosemont. University of Montreal) ;
Lazarus, H. (Case Western Reserve University) ;
Masszi, T. (St László Hospital (Hongria)) ;
Michallet, M. (Hematology Department. Groupement Hospitalier Sud. Hospices Civils de Lyon. Université Claude Bernard Lyon EST) ;
Nagler, Arnon (Hematology and Bone Marrow Transplantation. Chaim Sheba Medical Center) ;
NiChonghaile, M. (Trinity College Dublin) ;
Okamoto, S. (Division of Hematology. Department of Medicine. Keio University School of Medicine) ;
Pagliuca, A. (King's College Hospital NHS Foundation Trust) ;
Peters, C. (Department of Pediatrics. St. Anna Kinderspital) ;
Petersen, F. B. (LDS Hospital) ;
Richardson, Paul G.. (Division of Hematology. Mayo Clinic) ;
Ruutu, T. (Helsinki University Hospital (Finlàndia)) ;
Saber, Wael (Center for International Blood and Marrow Transplant Research. Medical College of Wisconsin) ;
Savani, B. N. (Hematology and Stem Cell Transplantation Section. Division of Hematology/Oncology. Department of Medicine. Vanderbilt University Medical Center and Veterans Affairs Medical Center) ;
Soiffer, R. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica). Division of Hematologic Malignancies) ;
Styczynski, Jan (Pediatric Hematology and Oncology. University Hospital. Collegium Medicum UMK) ;
Wallhult, E. (Sahlgrenska University Hospital (Suècia)) ;
Yakoub-Agha, Ibrahim (CHU de Lille. LIRIC INSERM U995. Université de Lille2) ;
Duarte, Rafael (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Carreras, Enric (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Universitat Autònoma de Barcelona
2020 - 10.1038/s41409-019-0705-z
Bone marrow transplantation, Vol. 55 Núm. 3 (january 2020) , p. 485-495
|
|
|
10.
|
|
8 p, 788.7 KB |
A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)
/
Hájek, R. (University Hospital Ostrava) ;
Masszi, T. (St László Hospital (Hongria)) ;
Petrucci, M. T. (Sapienza Università di Roma) ;
Palumbo, A. (Università di Torino) ;
Rosiñol, L. (Hospital Clínic i Provincial de Barcelona) ;
Nagler, Arnon. (Chaim Sheba Medical Center (Israel)) ;
Yong, K. L. (University College London Cancer Institute) ;
Oriol, Albert (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Minarik, J. (University Hospital Olomouc (Olomouc, República Txeca)) ;
Pour, L. (University Hospital Ostrava) ;
Dimopoulos, Meletios (The National and Kapodistrian University of Athens) ;
Maisnar, V. (Charles University. Faculty of Medicine in Hradec Králové) ;
Rossi, Davide (Amedeo Avogadro University of Eastern Piedmont) ;
Kasparu, H. (Ordensklinikum Linz Elisabethinen) ;
Van Droogenbroeck, J. (AZ Sint-Jan, Brugge, Belgium) ;
Yehuda, D. B. (Hadassah Medical Center, Jerusalem, Israel) ;
Hardan, I. (Meir Medical Center, Kfar-Saba, Israel) ;
Jenner, M. (University Hospital Southampton NHS Foundation Trust (Regne Unit)) ;
Calbecka, M. (Nicolaus Copernicus Hospital, Toruń Poland) ;
Dávid, M. (University of Pécs, Hungary) ;
de la Rubia, Javier (Hospital Universitari i Politècnic La Fe (València)) ;
Drach, J. (Medical University of Vienna) ;
Gasztonyi, Z. (Petz Aladár Megyei Oktató Kórház, Vasvári Pál, Hungary) ;
Górnik, S. (Zamojski Szpital Niepubliczny, Zamosc, Poland) ;
Leleu, Xavier (Hopital Huriez, CHRU, Lille, France) ;
Munder, M. (University Medicine Mainz, Germany) ;
Offidani, M. (Clinica di Ematologia Azienda Ospedaliero-Universitaria, Ospedali Riuniti di Ancona, Italy) ;
Zojer, N. (Center for Oncology, Hematology with Outpatient Department and Palliative Care, Wilhelminenspital, Vienna, Austria) ;
Rajangam, K. (Onyx Pharmaceuticals, Inc.) ;
Chang, Y. L. (Onyx Pharmaceuticals, Inc.) ;
San-Miguel, J. F. (Clínica Universidad de Navarra. Centro de Investigación Médica Aplicada) ;
Ludwig, H. (Wilhelminen Cancer Research Institute (Viena, Àustria))
This randomized, phase III, open-label, multicenter study compared carfilzomib monotherapy against low-dose corticosteroids and optional cyclophosphamide in relapsed and refractory multiple myeloma (RRMM). [...]
2017 - 10.1038/leu.2016.176
Leukemia, Vol. 31 (2017) , p. 107-114
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
